569250-U
Discovery® HS C18 (3 µm) HPLC Columns
L × I.D. 5 cm × 4.6 mm, HPLC Column
Synonym(s):
Discovery RP18 HPLC Column
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
5 cm × 4.6 mm
Particle size:
3 μm
Matrix active group:
C18 (octadecyl) phase
Pore size:
120 Å
Matrix:
silica gel, high purity, spherical particle platform, fully porous particle
Product Name
Discovery® HS C18 HPLC Column, 3 μm particle size, L × I.D. 5 cm × 4.6 mm
material
stainless steel column
Quality Level
agency
suitable for USP L1
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
20% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
5 cm × 4.6 mm
surface area
300 m2/g
surface coverage
3.2 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical particle platform, fully porous particle
matrix active group
C18 (octadecyl) phase
particle size
3 μm
pore size
120 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
reversed phase
Application
- A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).
- Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).
- Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).
Features and Benefits
- Stable, low bleed for LC-MS applications
- Scalable from analytical to preparatory
- Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility
- Higher hydrophobicity for better resolution of difficult analytes
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Discovery® HS C18 HPLC Column
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
HPLC DiscoveryBIO HS C18 products. Available in 3µm, 5µm and 10µm particle sizes.
Awantika Singh et al.
Rapid communications in mass spectrometry : RCM, 29(6), 485-496 (2015-07-15)
Adhatoda beddomei and Adhatoda vasica are popular Ayurvedic medicinal plants in India, belonging to the family Acanthaceae. Tricyclic quinazoline alkaloids are found to be the most abundant in these plants which are responsible for broad-spectrum medicinal properties. This study aims
Abad Khan et al.
Talanta, 84(3), 789-801 (2011-04-13)
A new, simple, economical and validated high-performance liquid chromatography linked with electrochemical detector (HPLC-ECD) method has been developed and optimized for different experimental parameters to analyze the most common monothiols and disulfide (cystine, cysteine, homocysteine, methionine, reduced (GSH) and oxidized
Swati Jaiswal et al.
Journal of chromatographic science, 55(6), 617-624 (2017-03-24)
Tuberculosis (TB) with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome represents the most common infectious diseases worldwide. Anti-TB drugs are used concurrently with antiretroviral drug for treatment of TB-HIV co-morbidities. Due to lower risk of interaction with protease inhibitors, rifabutin is
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 569250-U | 04061838545763 |